Results 71 to 80 of about 3,796,794 (238)

Biography as the Missing Variable in Drug Development: A Case for Bio‐Biographical Mechanistic Profiling

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
Most clinical trial failures reflect unmeasured biological heterogeneity. Biography — chronic stress, adversity, trauma, and social isolation—is a neglected source of that heterogeneity, operating through the same molecular pathways drugs engage.
Ralph I. Horwitz
wiley   +1 more source

Effects of transdermal estrogen replacement therapy on plasma levels of nitric oxide and plasma lipids in postmenopausal women

open access: yes, 2005
Objective: Our purpose was to assess the effects of transdermal estrogen replacement therapy (TERT) on plasma levels of nitric oxide (NO) and plasma lipids in postmenopausal ...
Kirkali, G   +11 more
core   +1 more source

Estrogen Replacement Therapy Induces Antioxidant and Longevity-Related Genes in Women after Medically Induced Menopause. [PDF]

open access: yesOxid Med Cell Longev, 2021
Borrás C   +8 more
europepmc   +1 more source

Initiation of Gabapentin with Opioids and Risk of Respiratory Cardiovascular and Opioid‐Related Adverse Events Following Surgery for Breast Cancer

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
Pain is a key determinant of quality‐of‐life following breast cancer surgery, the most common cancer operation in the United States. Gabapentinoids are frequently prescribed for pain management, yet their respiratory, cardiovascular, and opioid‐related adverse effects remain unclear.
Jyun‐Heng Lai   +12 more
wiley   +1 more source

Route-dependent endocrine and metabolic effects of estrogen replacement therapy

open access: yes, 2000
The route of estrogen replacement therapy has a major impact on the growth hormone (GH)-insulin-like growth factor-I (IGF-I) axis. Estrogen administration by the oral, but not the transdermal, route reduces IGF-I and increases GH levels in postmenopausal
Ho, K.K.Y., O'Sullivan, Anthony
core  

Maca extracts and estrogen replacement therapy in ovariectomized rats exposed at high altitude. [PDF]

open access: yesReprod Med Biol, 2021
Ybañez-Julca RO   +3 more
europepmc   +1 more source

Urogenital Infection Risk Associated With SGLT2 Inhibitors Versus DPP‐4 Inhibitors in Type 2 Diabetes and Chronic Kidney Disease: A Nationwide Target Trial Emulation

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
Although sodium‐glucose cotransporter‐2 inhibitors (SGLT2i) are recommended for patients with type 2 diabetes mellitus (T2DM) and chronic kidney disease (CKD), concerns regarding urogenital infections persist. Therefore, we evaluated the risk of urinary tract infection (UTI) and genital tract infection (GTI) after SGLT2i initiation in this population ...
Young‐Mi Ah   +4 more
wiley   +1 more source

Advancing Pregnancy and Pediatric Science through the NIH Transporter Elucidation Network

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
Human gestation is characterized by dynamic changes in maternal physiology and maturation of tissue functions before and after birth. The fetus and neonate are highly dependent upon transfer of maternal nutrients via the placenta and lactating mammary gland, which frequently involve selective membrane transporter proteins.
Joanne Wang   +16 more
wiley   +1 more source

A Precise Activity System for Pharmacogenetics Based on Estimation of CYP2D6 Allelic Percentage Activity from the International CEPAM Database

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
The polymorphic enzyme CYP2D6 contributes to the metabolism of many frequently prescribed drugs, causing substantial variability in drug exposure and treatment outcomes. Genotype‐based dosing recommendations currently rely on drug‐agnostic categorical CYP2D6 allele activity values (AVs), potentially leading to imprecise CYP2D6 phenotype classification ...
Fenja Klima   +90 more
wiley   +1 more source

Home - About - Disclaimer - Privacy